Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

22 Apr 25

Updated

08 Nov 25

Views

533

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-24.8%

7D

-2.4%

Loading

1Y

-24.8%

7D

-2.4%

You can edit this narrative until Nov 9 1:10 AM. Then, changes will post as Updates.

Author's Valuation

US$13.1150.2% undervalued

AnalystConsensusTarget Fair Value

Shared on 08 Nov 25

Fair value Decreased 0.76%

NVAX: Shifting To Licensing Will Drive Royalties And Upfront Payments

Novavax's analyst price target has been modestly reduced from $13.21 to $13.11 per share. This change reflects analysts' cautious optimism about the company's new licensing model, expected royalties, and commercial partnership opportunities.

Shared on 24 Oct 25

Fair value Increased 5.69%

The analyst price target for Novavax has been raised from $12.50 to $13.21. This reflects analyst confidence in the company’s transition to a licensing model as well as opportunities for revenue from new partnerships and technology platforms.

Shared on 04 Sep 25

Fair value Decreased 2.78%

Novavax’s consensus price target was modestly reduced, primarily due to a slight decline in its future P/E ratio, bringing fair value down from $12.86 to $12.50. What's in the News Reports indicate that the Trump administration and Robert F.

Shared on 01 May 25

Fair value Decreased 4.26%

AnalystConsensusTarget Fair Value

US$13.11

50.2% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

-39.03%

Biotech revenue growth rate

9.55%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.44%

Calculation

US$53.77m

Earnings '28

x

50.93x

PE Ratio '28

=

US$2.74b

Market Cap '28

US$2.74b

Market Cap '28

/

169.64m

No. shares '28

=

US$16.14

Share Price '28

US$16.14 Share Price '28

Discounted to 2025 @ 7.32% p.a.

=

US$13.06

Fair Value '25